Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQZXDW)

Drug Name

LUM001 Drug Info

Synonyms

SHP625

Indication

Disease Entry	ICD 11	Status	REF
Primary biliary cholangitis	DB96.1	Phase 2	[1]
Primary biliary cirrhosis	DB96.1	Phase 2	[2]
Primary sclerosing cholangitis	DB96.2	Phase 2	[3]
Progressive familial intrahepatic cholestasis	5C58.03	Phase 2	[3]
Structural developmental anomalies of liver	LB20.0	Phase 2	[3]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ileal sodium/bile acid cotransporter (SLC10A2)	TTPI1M5	NTCP2_HUMAN	Inhibitor	[4]
Sodium/bile acid cotransporter (SLC10A1)	TTWZRY5	NTCP_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Ileal sodium/bile acid cotransporter (SLC10A2)	DTT	SLC10A2	5.752	5.641	5.904	6.506

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Primary biliary cholangitis

ICD Disease Classification

DB96.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Ileal sodium/bile acid cotransporter (SLC10A2)	DTT	SLC10A2	2.54E-01	-0.06	-0.17

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02321306) An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.